Farhad Hafezi

Professor of Ophthalmology at the University of Geneva, Switzerland; Research Group Leader at the CABMM of the University of Zurich, Switzerland; Chief Medical Officer of the ELZA Institute, Zurich, Switzerland; Adjunct Clinical Professor of Ophthalmology at the USC Roski Eye Institute, Los Angeles, USA; and Visiting Professor at the Wenzhou Medical University, Wenzhou, China

Content by Farhad Hafezi:

Subspecialties Cornea / Ocular Surface

Corneal Cross-Linking: What’s New in 2023?

06/28/2023 | Farhad Hafezi | 7 min read

Farhad Hafezi - newest breakthroughs in keratoconus

Subspecialties COVID-19

Education Without Borders

05/26/2020 | Farhad Hafezi

From the podium to the webinar platform: providing access to learning for everyone

Subspecialties Pediatric

Think PINCO

09/12/2019 | Farhad Hafezi

How should we persuade children – particularly those with communication challenges – to co-operate during ophthalmic examinations?

Subspecialties Cornea / Ocular Surface

CXL Unbound

08/27/2019 | Farhad Hafezi

What drives progress in medicine? Identifying and meeting unmet needs

Subspecialties Cornea / Ocular Surface

Unlocking CXL’s Molecular Mysteries – With Mice

11/05/2015 | Farhad Hafezi

Swiss researchers have developed methods for performing corneal crosslinking with riboflavin and corneal biomechanical testing in mice – opening up the world of transgenics and molecular testing.

Subspecialties Cornea / Ocular Surface

PACK-CXL For All

05/19/2014 | Farhad Hafezi

The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling. The evidence suggests that PACK-CXL could have a dramatic impact on a major cause of global blindness… but only if the expensive, bulky technology (and the requirement for a corneal surgeon in a sterile operating theater) can be overcome. One company may have the answer.